Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Inclusion Criteria10

• Diagnosis of MG confirmed by:
• History of a positive serologic test for anti-AChR antibodies, and
• One of the following:
• History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation
• History of positive anticholinesterase test (e.g., edrophonium chloride test); or
• Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician
• Disease duration from MG onset ≤ 3 years before T-4 (Enrolment);
• MGFA class IIb to IV;
• Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria
• Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.